James Shannon - PROQR THERAPEUTICS Independent Member of the Supervisory Board
| 0PQ Stock | EUR 3.41 0.21 6.56% |
Insider
James Shannon is Independent Member of the Supervisory Board of PROQR THERAPEUTICS EO 04 since 2016.
| Age | 62 |
| Tenure | 8 years |
| Phone | 31 88 166 7000 |
| Web | http://www.proqr.com |
PROQR THERAPEUTICS Management Efficiency
The company has return on total asset (ROA) of (0.2628) % which means that it has lost $0.2628 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7451) %, meaning that it generated substantial loss on money invested by shareholders. PROQR THERAPEUTICS's management efficiency ratios could be used to measure how well PROQR THERAPEUTICS manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 7 records | INSIDER Age | ||
| John CPA | American Homes 4 | 63 | |
| Matthew Halliday | American Homes 4 | N/A | |
| Joanne Halliday | American Homes 4 | N/A | |
| Brian Reitz | American Homes 4 | 43 | |
| Philip Irby | American Homes 4 | N/A | |
| David CPA | American Homes 4 | 62 | |
| Megan Grabos | American Homes 4 | N/A | |
Management Performance
| Return On Equity | -0.75 | |||
| Return On Asset | -0.26 |
PROQR THERAPEUTICS Leadership Team
Elected by the shareholders, the PROQR THERAPEUTICS's board of directors comprises two types of representatives: PROQR THERAPEUTICS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PROQR. The board's role is to monitor PROQR THERAPEUTICS's management team and ensure that shareholders' interests are well served. PROQR THERAPEUTICS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PROQR THERAPEUTICS's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Antoine Papiernik, Independent Member of the Supervisory Board | ||
| Daniel Boer, Chairman of the Management Board, Chief Executive Officer | ||
| Dinko Valerio, Independent Chairman of the Supervisory Board | ||
| Naveed Shams, Chief Scientific Officer | ||
| Alison Lawton, Independent Member of the Supervisory Board | ||
| Theresa Heggie, Independent Member of the Supervisory Board | ||
| James Shannon, Independent Member of the Supervisory Board | ||
| Bart Filius, Independent Member of the Supervisory Board |
PROQR Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PROQR THERAPEUTICS a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.75 | |||
| Return On Asset | -0.26 | |||
| Operating Margin | (16.95) % | |||
| Shares Outstanding | 71.43 M | |||
| Shares Owned By Insiders | 20.89 % | |||
| Shares Owned By Institutions | 41.47 % | |||
| Revenue | 3.93 M | |||
| Gross Profit | 2.4 M | |||
| EBITDA | (66 M) | |||
| Net Income | (46.56 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in PROQR Stock
PROQR THERAPEUTICS financial ratios help investors to determine whether PROQR Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PROQR with respect to the benefits of owning PROQR THERAPEUTICS security.